NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
- Registration Number
- NCT04303117
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
Background:
Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of transplant. Researchers want to see if 2 non-chemotherapy drugs can help people with KS. NHS-IL12 triggers the immune system to fight tumors. M7824 blocks the pathways that cancer cells use to stop the immune system from fighting tumors.
Objective:
To learn if giving NHS-IL12 alone or with M7824 could help the immune system fight KS tumors.
Eligibility:
People 18 and older with KS that has been treated with chemotherapy or immunotherapy
Design:
Participants will be screened with some or all of the following:
medical history
physical exam
chest X-ray
computed tomography scan
blood and urine tests
electrocardiogram and echocardiogram
skin KS lesion biopsy
lung exam
gastrointestinal exam
All participants will get NHS-IL12 every 4 weeks for up to 96 weeks (or 24cycles). It is injected under the skin.
Some participants will also get M7824 every 2 weeks for up to 96 weeks (or 24cycles). It is given through a plastic tube that is put in an arm vein.
Participants will complete questionnaires about how KS affects their quality of life. Their KS lesions will be measured and photographed. They will repeat some of the screening tests. They will give saliva samples or additional tissue samples. They will have a lung function test. Their ability to perform their normal activities will be assessed. The treatment duration is up to 96 weeks (or 24cycles) with an option to take NHS-IL12 and/or M7824 until the KS tumors are not responding, or you develop unacceptable side effects.
Participants will have follow-up visits 7 and 30 days after treatment ends, then every 3 to 6 months for the next 18 months, then once a year for 3 years.
- Detailed Description
Background:
* Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is most common in people with HIV but may also occur in patients without a diagnosis of HIV. Patients with HIV-associated KS have worse survival than HIV-infected patients without KS.
* As it is a relapsing and remitting condition, patients with KS often require prolonged courses of cytotoxic chemotherapy.
* KS is an immune responsive tumor as interferon-alpha, pomalidomide, and restoring T-cell function in HIV + patients treated with antiretroviral drugs can result in clinical benefit and remission of KS.
* Published Phase I/II studies by our group demonstrated that IL-12 alone and in combination with liposomal doxorubicin led to clinical responses in patients with advanced KS.
* PDS01ADC is an immunocytokine with affinity to both single and double stranded DNA allowing for targeting of exposed DNA, which is commonly seen in necrotic tumors. This agent is able to deliver IL-12 to the tumor microenvironment promoting local immunomodulation, that results in less systemic toxicity than IL-12 systemic administration.
* M7824 is a novel bifunctional fusion protein composed of a monoclonal antibody against human PD-L1 (avelumab) fused with the extracellular domain of human TGF-beta receptor II (TGF-betaRII), which functions as a TGF-beta trap .
* Anti-PD-L1 and anti-PD-1 agents have been found to be active in certain virus-induced cancers, including Kaposi sarcoma, and to be safe and active in patients with HIV infection.
* Currently, no clinical data exists for the combination of PDS01ADC and M7824. Preclinical data suggest synergy between these agents from existing ongoing studies and the available clinical data both in KS and other tumor subtypes suggest that the combination of PDS01ADC with M7824 is likely to be well-tolerated and has scientific rationale. This combination offers a new treatment approach for patients with advanced KS who have received prior therapies.
Objectives:
-Evaluate the safety, tolerability, and activity of single agent PDS01ADC and the combination of PDS01ADC with M7824 in participants with advanced KS
Eligibility:
* Age \>=18 years
* Histologically confirmed Kaposi sarcoma (KS)
* KS requiring systemic therapy, with or without a history of prior systemic therapy
* At least five measurable cutaneous KS lesions with no previous local radiation, surgical or intralesional cytotoxic therapy to these measurable lesions.
* ECOG Performance Status (PS) \<= 2
* Participant must be willing to give informed consent.
* Participants can be HIV positive or negative.
* Antiretroviral therapy (ART) for HIV+ participants for 8 or more weeks prior to entry with an HIV viral load of \<400 copies/ml and CD4+ T-cell count \>50 cells/microliter.
* Participants with bleeding from visceral sites of KS or requiring blood transfusions in the 2 weeks prior to study entry will not be eligible.
Design:
* This is a Phase I/II study assessing the safety and efficacy of PDS01ADC alone or in combination with M7824 in participants with advanced KS. Participants will receive therapy until optimal tumor response, unacceptable toxicity, the participant s request to discontinue therapy, PI decision, up to a total of 96 weeks, or 24 cycles.
* Monotherapy: Participants with history of prior systemic therapy will receive PDS01ADC alone with a 3+3 design applicable to the first 3-6 participants at a starting dose of 16.8 microgram/kg on day 1 of a 28-day cycle. Two dose de-escalation levels (Dose Level -1: 12 microgram/kg or Dose Level -2: 8 microgram/kg) will be permitted if there is evidence of 2 or more dose limiting toxicities within the first 6 weeks of therapy. An expansion cohort will investigate the activity of PDS01ADC in participants with and without prior systemic therapy for KS.
* Combination Therapy: The combination arm will open following accrual and completion of the DLT period for participants in the monotherapy arm. Up to 28 participants will be treated with M7824 (1200 mg IV, every 2 weeks) and PDS01ADC (MTD dose from the monotherapy arm). The DLT period for this arm will be 6 weeks.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 64
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Arm 2/Combination therapy NHS-IL12 Treatment with NHS-IL12 at MTD and M7824 at a fixed dose Arm 1a/Monotherapy Expansion NHS-IL12 Treatment with NHS-IL12 at MTD Arm 2/Combination therapy M7824 Treatment with NHS-IL12 at MTD and M7824 at a fixed dose Arm 1/Monotherapy NHS-IL12 Treatment with NHS-IL12 at de-escalating doses if necessary
- Primary Outcome Measures
Name Time Method safety, tolerability and activity of NHS-IL12 alone or in combination with M7824 24 cycles of treatment, until confirmed progression, unacceptable toxicity or trial withdrawal The fraction of participants with toxicity noted at each dose level will be reported by grade and type of toxicity identified. Maximum tolerated dose will also be reported.
- Secondary Outcome Measures
Name Time Method duration of response every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years the time criteria are met for CR or PR (whichever is recorded first) until the first date that participant no longer qualifies as a PR
progression free survival every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years duration of time from the start of the treatment until time of disease relapse from PR, disease progression, or death, whichever occurs first
objective response rates every 3 months for the first 6 months after completion of therapy, then every six months for the next 18 months, and then annually for a total of 3 years Percentage of participants with the best overall response of CR or PR to therapy
Trial Locations
- Locations (1)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States